Probably non-CYP metabolism. No data pointing to any interaction with the metabolism of CYP-metabolised drugs.

(To be edited, initial data ST OCT 04) Selective inhibitor of intestinal cholesterol absorbtion. Mainly metabolized in the liver and intestinal wall via glucuroidation (phase II reaction) and eliminated via bile.

Uneventful use reported in 8 patients with acute porphyria.